Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases. Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). [...]
Lipum and some listed nordic life science companies will make company presentations in Stockholm at Nyhetsbyrån Direkt on August 29, 2018. The event is organised by Biostock and will also be broadcasted with start at 09:00. It is free of charge, sign up here.
An international panel of life science investors have selected Lipum as one of 12 companies for the final of the live pitch competition at the Nordic Life Science Days 2018. Learn more about Lipum and other successful companies. We will also attend the partnering activities during the NLSDays in Stockholm, Sept 10-12. Please contact us [...]
Our project "Validation of a biological candidate drug" has been granted support from SWElife "Projects for better health" program. The competition was fierce so the green tie was used during the interview and Lipum was then one of 22 projects granted. In total 123 applications were submitted, read more (Swedish). - This is a quality stamp [...]
Learn more about our novel target for treatment of chronic inflammatory diseases at Biotrinity - A Leading Biopartnering and Investment Conference in London, April 23-25, 2018 We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected original research data proving the efficacy of the [...]
Biotech Umeå Investment Day 2018 on February 1 at Grand Hôtel in Stockholm is a partnering event, for startups, investors and industrial partners within life science. Beside Lipum you can also meet other exciting life science companies from the top-ranked Umeå Biotech Incubator. In fact, there is an opportunity already on 31st of January 2018, 17:00-21:00 [...]
The European Molecular Biology Laboratory (EMBL) was founded more than 40 years ago to be a centre of excellence for Europe’s most talented young scientists in the life sciences. In the Alumni Impact Report 2017 companies co-founded by EMBL alumni are listed, among those Lipum AB and Prof Lennart Lundberg. Read the report here.
Seal of Excellence Certificate by European Commission In response to Lipums application ”Novel Target for Treatment of Chronic Inflammatory Diseases” for SME Instrument 2 funding by EU’s Horizon 2020 an international panel of independent experts scored it as a high-quality project proposal in a highly competitive evaluation process. The ”Seal of Excellence” certificate is issued for [...]
Learn more about our novel target for treatment of chronic inflammatory diseases. We will attend: BIO-Europe in Berlin, Nov 6-8 Nordic-American conference in New York, Nov 13-14 RESI meeting in New York, Nov 15 We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected [...]
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases. Lipum has collected original research data [...]